SCHEMBL1975413

SCHEMBL1975413

COc1ccc(-c2oc3c(OC)c(OC)c(C#CCCCCCCCCCCOCc4ccccc4)cc3c(=O)c2O)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 7/20 0.47
ABCB1 P08183 4/20 0.47
MAPT P10636 4/20 0.46
KDM4E B2RXH2 3/20 0.46
MEN1 O00255 2/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP3A4 P08684 2/20 0.46
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 2/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP1A1 P04798 5/20 0.42
CYP1A2 P05177 5/20 0.42
CYP1B1 Q16678 5/20 0.42
GAA P10253 1/20 0.42
ALOX5 P09917 1/20 0.40
ABCC1 P33527 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1974782 1.00 ABCG2 (0.47) ABCG2ABCB1MAPTKDM4EMEN1
SCHEMBL1975720 0.96 ABCG2 (0.43) ABCG2ABCB1MAPTKDM4EMEN1
SCHEMBL1975670 0.96 ABCG2 (0.43) ABCG2ABCB1MAPTKDM4EMEN1
SCHEMBL1975438 0.89 ABCG2 (0.48) ABCG2ABCB1MAPTKDM4EMEN1
SCHEMBL1976551 0.89 ABCG2 (0.48) ABCG2ABCB1MAPTKDM4EMEN1
SCHEMBL1976737 0.88 MAPT (0.51) ABCG2ABCB1MAPTKDM4EMEN1
SCHEMBL1976968 0.88 MAPT (0.51) ABCG2ABCB1MAPTKDM4EMEN1
SCHEMBL1973990 0.85 ABCG2 (0.44) ABCG2ABCB1MAPTKDM4EMEN1
SCHEMBL1976288 0.85 ABCG2 (0.44) ABCG2ABCB1MAPTKDM4EMEN1
SCHEMBL1976215 0.85 MAPT (0.47) ABCG2ABCB1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS (LU) 2011-06-16 US disclosed
EP-2112145-A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases AxoGlia Therapeutics S.A. (LU) 2009-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PARK7, CDR2, SNCA ABCG2 1767/4885ABCB1 2178/4885MAPT 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.